- Email: [email protected]
Eledoisin and fribrinolysis in man
Pharmacologica/ Research Communications, VoL 1, NO.2, 1969
188
ELEDOISIN AND FRIBRINOLYSIS IN MAN F. Pratesi, M. Tesi and L. Caramelli Department of Studies and Treatment of Circulatory Diseases, Main Hospital of S.Maria Nuova, Florence, Italy We injected eledoisin into the humeral artery and determined the fibrinolytic activity oi the venous return in the same limb. In two groups of 10 subjects, clinically healthy from the vascular point of view, two series of tests were carried out separately as follows: 1) Rapid administration (5 seconds) of 2 ug of eledoisin into the humeral artery and determination of the fibrinolytic activity and the rate of the proactivator in the venous return of the same limb both before and after injection. 2) Rapid intravenous administration of 2 ug of eledoisin and determination of fibrinolytic activity of the venous blood before and after the injection. 3) Slow intra-arterial administration of 2.5 ug of eledoisin per minute for 20 minutes and determination of the fibrinolytic activity in the returning venous blood and the quantity of the proactivator before and during the injection. 4) Addition of eledoisin in varying doses (0.5, 1, 1.5, 2 ug) in samples of blood (4 ml) and study of the haematic fibrinolytic activity "in vitro". For determination of the haematic fibfinolytic activity we used the Tillet-Andreotti method and Fearnley method: for determination of the quantity of the haematic proactivator we used the Blix method. 1) After administration of eledoisin into the artery of a limb, a marked increase in fibrinolytic activity is observed in the venous return. 2) Even with administration ofanequal dose of eledoisin by the venous route an increase in fibrinolysis in the venous blood of the opposite limb is generally noted. 3) Comparison of the increases obtained by the two routes of administration reproducibly and strikingly reveals that the increase obtained in the venous return of the limb into which eledoisin was injected by intra-arterial route is higher than that obtained by intravenous route. 4) After intra-arterial administration, the venous blood of the opposite limb presents an increase in fibrinolysis which is always remarkably inferior, sometimes to a marked degree, to the venous blood of the homolateral vein. 5) This increase in fibrinolysis observed in the vein of the opposite limb following intra-arterial injection of eledoisin was inferior to the increase obtained by intravenous administration. 6) During rapid or slow intra-arterial injection of eledoisin, the content of the proactivator in the venous return behaves inversely to that of fibrinolytic activity: while fibrinolytic activity progressively increases, the quantity of the haematic proactivator progressively diminishes. 7) Eledoisin brings about no increase in fibrinolysis "in vitro". These results tend to show that eledoisin has the capacity of stimulating vessel-wall fibrinolytic activity.
188
ELEDOISIN AND FRIBRINOLYSIS IN MAN F. Pratesi, M. Tesi and L. Caramelli Department of Studies and Treatment of Circulatory Diseases, Main Hospital of S.Maria Nuova, Florence, Italy We injected eledoisin into the humeral artery and determined the fibrinolytic activity oi the venous return in the same limb. In two groups of 10 subjects, clinically healthy from the vascular point of view, two series of tests were carried out separately as follows: 1) Rapid administration (5 seconds) of 2 ug of eledoisin into the humeral artery and determination of the fibrinolytic activity and the rate of the proactivator in the venous return of the same limb both before and after injection. 2) Rapid intravenous administration of 2 ug of eledoisin and determination of fibrinolytic activity of the venous blood before and after the injection. 3) Slow intra-arterial administration of 2.5 ug of eledoisin per minute for 20 minutes and determination of the fibrinolytic activity in the returning venous blood and the quantity of the proactivator before and during the injection. 4) Addition of eledoisin in varying doses (0.5, 1, 1.5, 2 ug) in samples of blood (4 ml) and study of the haematic fibrinolytic activity "in vitro". For determination of the haematic fibfinolytic activity we used the Tillet-Andreotti method and Fearnley method: for determination of the quantity of the haematic proactivator we used the Blix method. 1) After administration of eledoisin into the artery of a limb, a marked increase in fibrinolytic activity is observed in the venous return. 2) Even with administration ofanequal dose of eledoisin by the venous route an increase in fibrinolysis in the venous blood of the opposite limb is generally noted. 3) Comparison of the increases obtained by the two routes of administration reproducibly and strikingly reveals that the increase obtained in the venous return of the limb into which eledoisin was injected by intra-arterial route is higher than that obtained by intravenous route. 4) After intra-arterial administration, the venous blood of the opposite limb presents an increase in fibrinolysis which is always remarkably inferior, sometimes to a marked degree, to the venous blood of the homolateral vein. 5) This increase in fibrinolysis observed in the vein of the opposite limb following intra-arterial injection of eledoisin was inferior to the increase obtained by intravenous administration. 6) During rapid or slow intra-arterial injection of eledoisin, the content of the proactivator in the venous return behaves inversely to that of fibrinolytic activity: while fibrinolytic activity progressively increases, the quantity of the haematic proactivator progressively diminishes. 7) Eledoisin brings about no increase in fibrinolysis "in vitro". These results tend to show that eledoisin has the capacity of stimulating vessel-wall fibrinolytic activity.